Tri­al en­roll­ment is an ever-press­ing is­sue, yet so many pa­tients search­ing for hope face a process where they wait days for phone calls, weeks to have their med­ical da­ta tracked down and sort­ed through, and weeks—or even months—for on-site vis­its. The im­pact of this can be dev­as­tat­ing: mil­lions of dol­lars in costs for Spon­sors each year, failed stud­ies, and worst of all, less­er care for pa­tients that de­serve bet­ter. While en­roll­ment de­lays are of­ten treat­ed as a num­bers prob­lem, the re­al­i­ty is they are ac­tu­al­ly a mo­men­tum prob­lem. The dis­con­nect oc­curs when pa­tients and their loved ones seek new care op­tions, but the clin­i­cal tri­al ecosys­tem sim­ply can’t move fast enough to get them screened and en­rolled in a suit­able time­frame. It’s clear the in­dus­try needs to move at a speed that puts pa­tients first, and da­ta sup­ports that when that hap­pens, en­roll­ment pe­ri­ods short­en by an av­er­age of 3.5 months!

For­tu­nate­ly Clin­i­cal En­roll­ment and Pre­doc—two of the fastest grow­ing com­pa­nies in clin­i­cal tri­al re­cruit­ment and pa­tient da­ta—have part­nered to cre­ate a sys­tem that pri­or­i­tizes the pa­tient ex­pe­ri­ence, match­es pa­tient in­ter­est, and moves qual­i­fied can­di­dates from ini­tial in­ter­est to en­roll­ment in a mat­ter of days. And the best part is, they’re so con­fi­dent in their mod­el that they take on the fi­nan­cial risk. Spon­sors on­ly pay when pa­tients en­roll. That’s right. Ze­ro cost un­less pa­tients en­roll and move the tri­al for­ward.

Across ther­a­peu­tic ar­eas, Clin­i­cal En­roll­ment dri­ves rough­ly 30% of to­tal tri­al en­roll­ment be­cause of its ded­i­ca­tion to the pa­tient ex­pe­ri­ence. With Pre­doc em­bed­ded in the Clin­i­cal En­roll­ment fun­nel from the be­gin­ning of a tri­al, on­site vis­its have in­creased by up to 45%.

Here’s how it hap­pens:

• Pa­tient Screen­ing: Clin­i­cal En­roll­ment us­es al­go­rithms and be­hav­ioral tar­get­ing across dig­i­tal plat­forms to iden­ti­fy pa­tient pools. Pa­tients are con­tact­ed with­in five min­utes of ex­press­ing in­ter­est, kick­start­ing a dual screen­ing process to en­sure high­ly qual­i­fied can­di­dates, and hu­man touch­points through­out that serve as a trust­ed source to an­swer ques­tions and al­lay con­cerns. The pay­off: on-site to in­formed con­sent rate av­er­ages 89%, and screen-fail rates run ap­prox­i­mate­ly 18% be­low study av­er­ages.
• Med­ical Records Re­trieval and Re­view: Pre­doc elec­tron­i­cal­ly re­trieves com­plete med­ical records in three to five days in­stead of five to six weeks. Then, Pre­doc us­es the da­ta with­in the record to an­swer study I/E cri­te­ria with clin­i­cian lev­el ac­cu­ra­cy so that when pa­tients are re­ferred to sites, they are re­ferred both hav­ing been more rig­or­ous­ly screened than any­where else in the in­dus­try, and al­ready with med­ical records in hand. Not on­ly does this lift the bur­den from the sites, but it al­so cares for the pa­tient and their time.
• White Glove Clin­i­cal Site Re­la­tions: Clin­i­cal En­roll­ment part­ners with clin­i­cal sites every step of the way to make sure its process is op­ti­miz­ing for site band­width. One time sav­ings ef­fort: sites re­ceive a one-page clin­i­cal ref­er­ence and analy­sis of where the pa­tient sits with­in the can­di­date pool. The more con­text sites have on re­fer­rals, the more they can do to cre­ate a mean­ing­ful site ex­pe­ri­ence for pa­tients and their loved ones.
• Suc­cess-Based Pric­ing: Spon­sors don’t pay for im­pres­sions, re­fer­rals, or ac­tiv­i­ty. They pay when pa­tients are ac­tu­al­ly en­rolled. When com­bined with Pre­doc’s rapid elec­tron­ic med­ical record re­trieval, the mod­el re­moves both op­er­a­tional drag and fi­nan­cial un­cer­tain­ty.

Clin­i­cal En­roll­ment and Pre­doc’s mod­el means that, on av­er­age, pro­grams are able to fin­ish en­roll­ment rough­ly three and a half months ear­li­er than planned, and with av­er­age re­cruit­ment cy­cle cost sav­ings of $19+ mil­lion. Mean­ing med­ical break­throughs that change lives can hap­pen even faster.

Clin­i­cal tri­al re­cruit­ment will al­ways in­volve un­cer­tain­ty. But mo­men­tum and the pa­tient ex­pe­ri­ence is the dif­fer­ence be­tween stalled tri­als and suc­cess­ful ones, and that’s ex­act­ly what Clin­i­cal En­roll­ment and Pre­doc de­liv­er.

Both lead­er­ship teams are at SCOPE. If you’d like to learn more, click here.

Con­tribut­ing Au­thors: 

About Clin­i­cal En­roll­ment: Start­ed by a pa­tient for pa­tients, Clin­i­cal En­roll­ment ex­ists to make sure that no clin­i­cal tri­al fails be­cause it couldn’t meet en­roll­ment goals. Clin­i­cal En­roll­ment op­er­ates with a dig­i­tal-first hu­man­i­ty meets an­a­lyt­ics method­ol­o­gy de­signed to gen­er­ate at­ten­tion with­in rel­e­vant and hard-to-reach pa­tient pop­u­la­tions, and de­liv­ers un­prece­dent­ed re­sults to sites and spon­sors. 

About Pre­doc: 2026 SCOPE Site In­no­va­tion Award Nom­i­nee, Pre­doc works to im­prove hu­man health by con­nect­ing and or­ga­niz­ing the na­tion’s health­care da­ta so that health­care teams have ac­cess to the right da­ta at the right time. All in pur­suit of im­prov­ing hu­man health.

GSK no longer plans to col­lab­o­rate on a close­ly-watched RNA edit­ing pro­gram from Wave Life Sci­ences, whose fate could in­flu­ence the prospects of the emerg­ing field.

Wave an­nounced Mon­day that GSK re­turned rights to its RNA edit­ing treat­ment for AATD, a rare con­di­tion that can dam­age the lungs and liv­er. Wave’s ex­per­i­men­tal treat­ment is among the RNA-edit­ing pro­grams that are fur­thest along in clin­i­cal tri­als.

GSK was meant to take over work on that pro­gram af­ter Wave com­plet­ed its Phase 1/2 clin­i­cal study, as part of an ex­pan­sive 2022 deal be­tween the two com­pa­nies, but now Wave will have to move the RNA edit­ing treat­ment for­ward on its own. That part­ner­ship, which was for up to eight pro­grams, is still on­go­ing.

Genen­tech will pick up an RNAi can­di­date from Sa­ne­geneBio, a Chi­na and US biotech fresh off a $110 mil­lion Se­ries B.

The Roche unit will pay $200 mil­lion up­front for the glob­al li­cense to one of the biotech's RNAi pro­grams and even­tu­al­ly could fork over as much as $1.5 bil­lion in biobucks, Sa­ne­geneBio said Mon­day morn­ing. The name of the pro­gram was kept un­der wraps.

The deal is at least the 14th so far this year be­tween a West­ern bio­phar­ma and a drug de­vel­op­er with op­er­a­tions in Chi­na. Roche did an ADC deal with MediLink at the be­gin­ning of Jan­u­ary.

Genen­tech’s RNAi work in­cludes its Al­ny­lam-part­nered hy­per­ten­sion drug can­di­date zilebe­sir­an. It&r